Study on the Body Mass Balance and Biotransformation of [14C]-HEC585

April 11, 2023 updated by: Sunshine Lake Pharma Co., Ltd.

Clinical Trial of Absorption, Metabolism and Excretion of [14C]-HEC585 in Chinese Adult Male Healthy Subjects

This is a single-centre, open-label, non-randomised, single-dose study in healthy male subjects designed to assess the mass balance and biotransformation of [14C]-HEC-585.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

6

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Jiangsu
      • Suzhou, Jiangsu, China, 215006
        • The First Affiliated Hospital of Soochow University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Healthy males, age: 18 to 45 years old (including the critical value);
  2. The body weight is not less than 50 kg, and the body mass index (BMI) is in the range of 19.0~26.0 kg/m2 (including the critical value);
  3. Voluntarily participate in this trial, sign the informed consent form before the trial begins, and fully understand the trial content, process and possible risks;
  4. Subjects were able to communicate well with investigators and were able to complete the trial as specified in the protocol.

Exclusion Criteria:

  1. Comprehensive physical examination, vital signs, laboratory tests [blood routine, blood biochemistry, urine routine, coagulation function, fecal occult blood, thyroid function test (FT3, FT4, TSH)], 12-lead electrocardiogram, X-chest X-ray (frontal) or chest CT, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen and kidneys), new crown screening (nucleic acid + C-reactive protein) and other abnormal and clinically significant examinations;
  2. Those who are positive for any one of hepatitis B surface antigen or E antigen, hepatitis C antibody, HIV antibody and syphilis antibody;
  3. Those who have taken any drugs that inhibit or induce liver metabolism of drugs within 28 days before screening (see Appendix 1 for details);
  4. Use of any prescription or over-the-counter medicines, any vitamin products, health medicines or Chinese herbal medicines within 14 days prior to screening;
  5. Those who participated in any clinical trial and received intervention of experimental drugs or medical devices within 3 months before the screening period;
  6. Those who have been vaccinated within 1 month before screening or have a vaccination plan during the trial;
  7. Have any clinical history of serious diseases or diseases or conditions that the researchers believe may affect the results of the test, including but not limited to the circulatory system, endocrine system, nervous system, digestive system, urinary system or blood, immune, mental and metabolic diseases history;
  8. Those who have had heart failure, angina pectoris, myocardial infarction, clinically significant arrhythmia and other heart diseases in the past;
  9. Those who have undergone major surgery within 6 months before the screening period or the surgical incision is not completely healed. Major surgery includes but is not limited to any surgery with significant bleeding risk, prolonged general anesthesia, or incision biopsy or obvious traumatic injury ;
  10. Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 6 months before screening;
  11. Have clinically significant bleeding symptoms or a clear bleeding tendency within 3 months before screening, such as gastrointestinal bleeding, hemorrhagic gastric ulcer;
  12. Hemorrhoids or perianal diseases with regular/hematochezia, abnormal gastrointestinal function such as irritable bowel syndrome and inflammatory bowel disease, which may affect drug absorption as judged by the researchers;
  13. People with allergies, including drug allergies or food allergies, or those who have special requirements for diet and cannot follow a unified diet;
  14. Habitual constipation or diarrhea;
  15. Binge drinking or frequent drinking within 6 months prior to the screening period, i.e. drinking more than 14 units of alcohol per week (1 unit = 285 mL of beer or 25 mL of 40% alcohol or 100 mL of wine) or alcohol during the screening period Breath test results ≥ 20 mg/dL;
  16. Those who smoked more than 5 cigarettes or habitually used nicotine-containing products in the first 3 months of the screening period, and were unable to quit during the trial;
  17. Drug abuse or use of soft drugs (such as marijuana) 3 months before the screening period or hard drugs (such as: cocaine, amphetamines, phencyclidine, etc.) 1 year before the screening period, or urine drugs during the screening period ( Drugs) screening test positive;
  18. Habitual drinking of grapefruit juice or excessive tea, coffee and/or caffeinated beverages and unable to quit during the trial period;
  19. Those with a history of fainting of needles or blood, difficult to collect blood or unable to tolerate venipuncture for blood collection;
  20. Workers who need to be exposed to radioactive conditions for a long time, or have significant radioactive exposure (≥2 chest/abdominal CT, or ≥3 other types of X-ray examinations) within 1 year before the test, or have participated in radiopharmaceutical labeling experimenter;
  21. Those who have fertility plans during the trial and within 12 months after the administration of the trial drug, or who do not agree that the subjects and their spouses should take strict contraceptive measures during the trial and within 12 months after the administration of the trial drug (see details for details). Appendix 2);
  22. Those who have lost blood or donated blood up to 400 mL within 3 months before the screening period, or who have received blood transfusion, or who plan to donate blood within 3 months after the end of this trial;
  23. According to the judgment of the investigator, the subject has other factors that make it inappropriate to participate in this trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: [14C]-HEC585
[14C]-HEC585,solid powder，200 mg/100 µCi,single dose，oral
Drug: [14C]-HEC585
Single Dose = Solution containing 200 mg/100 µCi [14C]-HEC585

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mass balance
Time Frame: plasma up to 312 hours post dose, urine and fecal samples up to 504 hours post dose
To determine the mass balance recovery of orally administered [14C]-HEC585
plasma up to 312 hours post dose, urine and fecal samples up to 504 hours post dose

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peak Plasma Concentration (Cmax) of HEC-585 and its major metabolites
Time Frame: 312 hours
Analyze the Peak Plasma Concentration (Cmax) of HEC-585 and its major metabolites (if applicable) to obtain the corresponding pharmacokinetic parameters;
312 hours
Area under the plasma concentration versus time curve (AUC) of HEC-585 and its major metabolites
Time Frame: 312 hours
Analyze the Area under the plasma concentration versus time curve (AUC) of HEC-585 and its major metabolites (if applicable) to obtain the corresponding pharmacokinetic parameters;
312 hours
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: 504 hours
To investigate the safety and tolerability of HEC585 by assessment of Incidence of Treatment-Emergent Adverse Events following administration of of oral dose of 200 mg/100 µCi[14C]-HEC-585
504 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sunshine Lake Pharma Co., Ltd.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 26, 2022

Primary Completion (Actual)

August 14, 2022

Study Completion (Actual)

August 29, 2022

Study Registration Dates

First Submitted

May 12, 2022

First Submitted That Met QC Criteria

July 19, 2022

First Posted (Actual)

July 21, 2022

Study Record Updates

Last Update Posted (Actual)

April 13, 2023

Last Update Submitted That Met QC Criteria

April 11, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • HEC585-IPF-103

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Volunteer

Clinical Trials on [14C]-HEC585

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe